Sold Price for 39 Myrna Road Strathfield NSW 2135 39 Myrna Road Strathfield Unlimited Potential Situated in a peaceful location is this neat 2 bedroom brick residence set on a 15.24m x 41.18m or 626m2 block. Ideally located close to St Patrick’s College, parks and Cave Road Shops. Main Features: Separate lounge and dining, modern kitchen with granite benchtops, original bathroom, polished timber flooring, sunroom and off street parking for several cars. Summary: This home offers enormous potential to either extend or rebuild your
Wholesale NFL jerseys future dream home in a sought after location. View Auction Results Property No. 119507163 Page Visits: 1,344Outdoor Features Carport Spaces:3 Floorplans Interactive Tours Virtual Tour strathfield Suburb Profile Market DataThinking of living in strathfield? Explore the prices, people and lifestyle that’s on offer. Prepared by Local Sales Address Price Beds Sale Type Sale Date 33 Howard St $2,105,000 4 Auction 06/06/15 2 Sherars Av $2,610,000 4 Auction 05/06/15 94 Albyn Rd $2,955,000 5 Auction 31/05/15 23 South St $3,250,000 4 Auction 30/05/15 49 Myrna Rd $1,811,000 3 Auction 30/05/15 75 Redmyre Rd $4,165,000 4 Auction 30/05/15 60 Albert Rd $2,734,000 3 Auction 30/05/15 24 Elwin St $550,000 4 Normal Sale 29/05/15 25 Arthur St $1,783,000 3 Auction 24/05/15 58 Wallis Av $3,060,000 5 Auction 23/05/15 $9.90 report Get prices and estimated values of all properties sold in Strathfield in the last year. The information provided is deemed reliable but not guaranteed. The information provided is deemed reliable but not guaranteed. Contains property sales information provided under licence from the Department of Lands NSW.

Higher dose of Novartis drug Exelon 4, 2012 /PRNewswire/ The US Food and Drug Administration has approved a higher dose of Exelon Patch (rivastigmine transdermal system) for the treatment of people with mild to moderate Alzheimer’s disease. The new 13.3 mg/24 h dosage strength of Exelon Patch provides physicians with a new treatment option for
Cheap jerseys from China patients who are experiencing a decline in overall function and cognition. "Alzheimer’s disease is marked by progressive symptomatic decline, resulting in an increasingly large physical and emotional challenge for the patient and caregiver," said Jeffrey Cummings, MD, Director of the Cleveland Clinic Lou Ruvo Center for Brain Health. "Having multiple options for the treatment of mild to moderate Alzheimer’s disease will help physicians better care for patients with the hope of improving function and cognition." Approval of Exelon Patch 13.3 mg/24 h was based on the 48 week double blind phase of the OPTIMA study, a novel controlled

Articles Connexes:

Articles Connexes:

Tags